
Lonza Group AG
LZAGY
Updated: 23/09/2026, 01:42:12
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
No summaries found.
- Share price
- $68.63
- Market cap
- $48.83B
- Exchange
- OTC
- Currency
- USD
- CEO
- Wolfgang Wienand
- Employees
- 16,866
- IPO date
- 20/01/2010
- Beta
- 0.839
- Last dividend
- $0.00
- Day range
- $67.96 – $68.66
- 52-week range
- $58.53 – $74.36
- 1-day performance
- 2.43%
- 1-year performance
- 17.26%
- Current drawdown (1Y)
- -7.71%
- CIK
- N/A
- CUSIP
- 54338V101
- ISIN
- US54338V1017
- Created
- 07/12/2025, 05:08:34
- Last update
- 23/09/2026, 01:42:12
Track Lonza Group AG with an AI analyst
See which prediction-market events move LZAGY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Lonza: Structural Growth Intact, CHI Exit Strengthens Focus, Recent Weakness Reinforces Entry Opportunity
Seeking Alpha • STOCK • 01/04/2026, 08:03:33
Lonza Group AG (LZAGY) Discusses Divestment of Capsules and Health Ingredients Business and Focus on CDMO Transformation Transcript
Seeking Alpha • STOCK • 09/03/2026, 06:05:55